FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022772258> ?p ?o ?g. }

• W2022772258 endingPage "68" @default.
• W2022772258 startingPage "62" @default.
• W2022772258 abstract "Background Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR). Objective To evaluate the time to onset of action of ciclesonide, 200 μg/d, in patients with seasonal AR (SAR). Methods In a double-blind, randomized, placebo-controlled study conducted in an environmental exposure chamber, 509 adults with at least a 2-year history of SAR completed 1 to 5 priming sessions of ragweed pollen exposure (mean [SD] of 3,500 [500] grains/m3). Patients with successful priming visits (defined as patient-assessed instantaneous total nasal symptom scores [TNSSs] ≥6 and rhinorrhea or nasal congestion scores ≥2) received a single dose of intranasal ciclesonide, 200 μg (n = 255), or placebo (n = 254). The difference in the change from baseline in TNSSs between the ciclesonide and placebo groups was measured hourly 1 to 12 hours after study drug administration. Results At hour 6, the mean treatment difference in TNSSs between ciclesonide and placebo was 0.53 (95% confidence interval, 0.03-1.03; P = .02). Significant treatment differences in favor of ciclesonide were also observed at 2 additional time points: hour 10 (P = .01) and hour 12 (P = .008). Conclusions These results confirm that intranasal ciclesonide, 200 μg/d, has an onset of action of 6 hours in patients with SAR. Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR). To evaluate the time to onset of action of ciclesonide, 200 μg/d, in patients with seasonal AR (SAR). In a double-blind, randomized, placebo-controlled study conducted in an environmental exposure chamber, 509 adults with at least a 2-year history of SAR completed 1 to 5 priming sessions of ragweed pollen exposure (mean [SD] of 3,500 [500] grains/m3). Patients with successful priming visits (defined as patient-assessed instantaneous total nasal symptom scores [TNSSs] ≥6 and rhinorrhea or nasal congestion scores ≥2) received a single dose of intranasal ciclesonide, 200 μg (n = 255), or placebo (n = 254). The difference in the change from baseline in TNSSs between the ciclesonide and placebo groups was measured hourly 1 to 12 hours after study drug administration. At hour 6, the mean treatment difference in TNSSs between ciclesonide and placebo was 0.53 (95% confidence interval, 0.03-1.03; P = .02). Significant treatment differences in favor of ciclesonide were also observed at 2 additional time points: hour 10 (P = .01) and hour 12 (P = .008). These results confirm that intranasal ciclesonide, 200 μg/d, has an onset of action of 6 hours in patients with SAR." @default.
• W2022772258 created "2016-06-24" @default.
• W2022772258 creator A5026361524 @default.
• W2022772258 creator A5059729118 @default.
• W2022772258 creator A5076385418 @default.
• W2022772258 creator A5086462615 @default.
• W2022772258 date "2009-01-01" @default.
• W2022772258 modified "2023-09-25" @default.
• W2022772258 title "Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis" @default.
• W2022772258 cites W1968972903 @default.
• W2022772258 cites W1973755752 @default.
• W2022772258 cites W1976073672 @default.
• W2022772258 cites W1977323384 @default.
• W2022772258 cites W1983826704 @default.
• W2022772258 cites W1984622531 @default.
• W2022772258 cites W1988826107 @default.
• W2022772258 cites W2001450061 @default.
• W2022772258 cites W2002383915 @default.
• W2022772258 cites W2004874790 @default.
• W2022772258 cites W2010029246 @default.
• W2022772258 cites W2019259561 @default.
• W2022772258 cites W2028204150 @default.
• W2022772258 cites W2050754716 @default.
• W2022772258 cites W2054737698 @default.
• W2022772258 cites W2058214593 @default.
• W2022772258 cites W2073100929 @default.
• W2022772258 cites W2073909120 @default.
• W2022772258 cites W2089714786 @default.
• W2022772258 cites W2109995350 @default.
• W2022772258 cites W2115258511 @default.
• W2022772258 cites W2127586348 @default.
• W2022772258 cites W2154299860 @default.
• W2022772258 cites W2155318134 @default.
• W2022772258 cites W2163761361 @default.
• W2022772258 cites W53177715 @default.
• W2022772258 cites W82747538 @default.
• W2022772258 doi "https://doi.org/10.1016/s1081-1206(10)60110-x" @default.
• W2022772258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19205288" @default.
• W2022772258 hasPublicationYear "2009" @default.
• W2022772258 type Work @default.
• W2022772258 sameAs 2022772258 @default.
• W2022772258 citedByCount "12" @default.
• W2022772258 countsByYear W20227722582013 @default.
• W2022772258 countsByYear W20227722582015 @default.
• W2022772258 countsByYear W20227722582017 @default.
• W2022772258 countsByYear W20227722582019 @default.
• W2022772258 countsByYear W20227722582020 @default.
• W2022772258 countsByYear W20227722582021 @default.
• W2022772258 countsByYear W20227722582023 @default.
• W2022772258 crossrefType "journal-article" @default.
• W2022772258 hasAuthorship W2022772258A5026361524 @default.
• W2022772258 hasAuthorship W2022772258A5059729118 @default.
• W2022772258 hasAuthorship W2022772258A5076385418 @default.
• W2022772258 hasAuthorship W2022772258A5086462615 @default.
• W2022772258 hasConcept C126322002 @default.
• W2022772258 hasConcept C142724271 @default.
• W2022772258 hasConcept C204787440 @default.
• W2022772258 hasConcept C27081682 @default.
• W2022772258 hasConcept C2776042228 @default.
• W2022772258 hasConcept C2776804153 @default.
• W2022772258 hasConcept C2777588912 @default.
• W2022772258 hasConcept C2780973058 @default.
• W2022772258 hasConcept C2991922776 @default.
• W2022772258 hasConcept C42219234 @default.
• W2022772258 hasConcept C44249647 @default.
• W2022772258 hasConcept C71924100 @default.
• W2022772258 hasConcept C85663871 @default.
• W2022772258 hasConcept C98274493 @default.
• W2022772258 hasConceptScore W2022772258C126322002 @default.
• W2022772258 hasConceptScore W2022772258C142724271 @default.
• W2022772258 hasConceptScore W2022772258C204787440 @default.
• W2022772258 hasConceptScore W2022772258C27081682 @default.
• W2022772258 hasConceptScore W2022772258C2776042228 @default.
• W2022772258 hasConceptScore W2022772258C2776804153 @default.
• W2022772258 hasConceptScore W2022772258C2777588912 @default.
• W2022772258 hasConceptScore W2022772258C2780973058 @default.
• W2022772258 hasConceptScore W2022772258C2991922776 @default.
• W2022772258 hasConceptScore W2022772258C42219234 @default.
• W2022772258 hasConceptScore W2022772258C44249647 @default.
• W2022772258 hasConceptScore W2022772258C71924100 @default.
• W2022772258 hasConceptScore W2022772258C85663871 @default.
• W2022772258 hasConceptScore W2022772258C98274493 @default.
• W2022772258 hasIssue "1" @default.
• W2022772258 hasLocation W20227722581 @default.
• W2022772258 hasLocation W20227722582 @default.
• W2022772258 hasOpenAccess W2022772258 @default.
• W2022772258 hasPrimaryLocation W20227722581 @default.
• W2022772258 hasRelatedWork W2002451020 @default.
• W2022772258 hasRelatedWork W2017778565 @default.
• W2022772258 hasRelatedWork W2034925665 @default.
• W2022772258 hasRelatedWork W2038845306 @default.
• W2022772258 hasRelatedWork W2079641695 @default.
• W2022772258 hasRelatedWork W2084301163 @default.
• W2022772258 hasRelatedWork W2169432118 @default.
• W2022772258 hasRelatedWork W2768107310 @default.
• W2022772258 hasRelatedWork W4205539451 @default.
• W2022772258 hasRelatedWork W4253885304 @default.
• W2022772258 hasVolume "102" @default.

• next